SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. They have a team of investment professionals, located in the US and UK. As a team, their experience spans basic science, industry and the market. They take an active role in their portfolio companies and work with management teams and fellow venture investors to create significant value. Their current portfolio includes approximately 30 private and public companies and since its founding in 1985, they have invested over $680MM in the biotech space. Their expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.